Pharmacokinetics and Pharmacodynamics of Desmopressin Oral Lyophilisate Formulation in the Paediatric Population
Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
Patients suffering from nocturnal enuresis (starting from the age of 5 till adulthood) are
all treated with the same dose of desmopressin, i.e. 120mcg once daily. In treatment
resistant enuresis, this dose is doubled: those patients take 240mcg once daily. A pilot
study performed at our department showed a correlation between weight and plasma
concentration when a fixed dose of desmopressin oral lyophilisate formulation was given to
the pediatric patient (older than 6 years). This study will investigate the pharmacokinetics
(PK) and pharmacodynamics (PD) of desmopressin in young children, less than 8 years old.
Additionally, the efficacy of desmopressin oral lyophilisate formulation in urinary
concentration testing will be evaluated